CancerSlayer wrote:
Camphikefish wrote: I get bored I guess and like to look at "lesser" companies chart/price history in order to grasp what could be at hand for Theralase . If you are able to draw custom charts go and draw a January 2016 - August 2016 chart for SESN . The stock went from .25 to $6.00 in roughly 6 months . We all know what happened ultimately however, it is simply a historical comment showing what the market can do in a relatively short period of time based on speculation . The 1433 science we currently have coupled with 1633, the new compound Sherri just discovered for hypoxic tumors, Covid 99.99 kill rate, floor space at La Ki Shings lab, GBM / NSCLC imminent trials, built in ongoing immunity after treatment, protection of surrounding healthy cells, 1-2 treatments only ( or more if needed ) , availability of product , proven long term shelf life stability , comprehensive protected world wide patents , world renowned physician advocacy / speakers , undisclosed future indications and so on and so forth to infinity and beyond it seems . I lack the intelligence of Enrique ( who I am very thankful for by the way ) and many others here but I think I understand what I'm looking at when I see it . Watch out you shorters when it jumps to a dollar over night , then 2,3,4,5,6 and up . You will lose your shorts and we'll be wearing ours in the BVI .
Thanks for that nice post camphikefish...one can certainly learn a good lesson about speculation when considering SESN's chart history. Not only was their data lackluster (see below), there seems to have been more questions behind the data that may have led to the FDA rejection. An 8/2021 investigation by STAT revealed multiple concerns re: trial conduct, study violations & unrevealed drug toxicity. It's reasonable to think they may have dug a hole that's too deep to climb out of, hence the dramatic fall in share price. Their CR data amongst 89 patients with CIS (with or w/o papillary disease) was as follows: 40% at 3 months, 28% at 6 months, 21% at 9 months & 17% at 12 months. The CR rate drops off pretty significantly despite the number of treatments given...advantage TLT.
I know we've addressed this ad nauseum, but it doesn't hurt to review....Looking at our optimized Phase 2 data only & excluding the 7 pending patients, we are already at a 44% CR rate at 3 months (8/18 with 1 NR, 2 PR, 7 pending). If just half the PR & pending patients can also achieve a CR (very achievable imo), that would put us at nearly a 70% CR rate...with the realistic possibility of being higher. Just need to keep the house/trial sites/protocols in order, which I'm much more confident we can maintain...now that we have Dr. Madzarevic in house. Good luck...